Clinical Trial

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Study acronym: FIRST-NEC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-26; most recent amendment 2024-08-01.
Status change: Not Yet Recruiting → Recruiting 2024-08-01
Trial Details
NCT Number NCT06393816
Lead Sponsor Centre Leon Berard
Collaborators: Groupe Francais De Pneumo-Cancerologie
Conditions Large Cell Neuroendocrine Carcinoma of the Lung
Enrollment 80 participants
Start Date 2024-06-13
Primary Completion 2028-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2024-08-02